Caribou Biosciences, Inc (CRBU) Files up to $100M IPO

Caribou Biosciences, Inc (NASDAQ: CRBU) files for up to $100,000,000 IPO.

Caribou is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying a novel CRISPR platform, CRISPR hybrid RNA-DNA, or chRDNA, pronounced “chardonnay,” toward the development of next-generation, genome-edited cell therapies. CRBU's renowned founders, including a Nobel laureate, are pioneers in CRISPR genome editing. Their chRDNA technology has demonstrated superior specificity and high efficiency in preclinical studies, which enables them to perform multiple, precise genomic edits, while maintaining genomic integrity.

BofA Securities, Citigroup and SVB Leerink will serve as underwriters.

You May Also Be Interested In

• Rubrik IPO: 5 key things to know
• Jiade Limited (JDZG) Files for 2.2M Share IPO at $4-$5/sh
• Canopy Growth (CGC) Announces CBI Conversion to Exchangeable Shares, Appoints New Board